These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34499866)

  • 41. Interstitial lung diseases in the hospitalized patient.
    Disayabutr S; Calfee CS; Collard HR; Wolters PJ
    BMC Med; 2015 Sep; 13():245. PubMed ID: 26407727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interstitial lung disease: trials and tribulations.
    Afshar K; Sharma OP
    Curr Opin Pulm Med; 2008 Sep; 14(5):427-33. PubMed ID: 18664973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases.
    King C; Nathan SD
    Curr Opin Pulm Med; 2013 Sep; 19(5):466-73. PubMed ID: 23912191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.
    Swigris JJ; Brown KK; Abdulqawi R; Buch K; Dilling DF; Koschel D; Thavarajah K; Tomic R; Inoue Y
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapy for idiopathic interstitial pneumonias: steroids--and what else?].
    Prasse A; Müller-Quernheim J
    Internist (Berl); 2006 Dec; 47(12):1258-62. PubMed ID: 17102999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
    Wu C; Lin H; Zhang X
    Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spectrum of fibrosing diffuse parenchymal lung disease.
    Morgenthau AS; Padilla ML
    Mt Sinai J Med; 2009 Feb; 76(1):2-23. PubMed ID: 19170214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of acute exacerbations of interstitial lung disease.
    Azadeh N; Moua T; Baqir M; Ryu JH
    Expert Rev Respir Med; 2018 Apr; 12(4):309-313. PubMed ID: 29486130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study.
    Tanizawa K; Handa T; Kubo T; Chen-Yoshikawa TF; Aoyama A; Motoyama H; Hijiya K; Yoshizawa A; Oshima Y; Ikezoe K; Tokuda S; Nakatsuka Y; Murase Y; Nagai S; Muro S; Oga T; Chin K; Hirai T; Date H
    Respir Res; 2018 Aug; 19(1):162. PubMed ID: 30165854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
    de Lauretis A; Veeraraghavan S; Renzoni E
    Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Recognition of interstitial lung diseases].
    Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 2014; 82(3):191-3. PubMed ID: 24793145
    [No Abstract]   [Full Text] [Related]  

  • 55. Interstitial lung diseases.
    Wijsenbeek M; Suzuki A; Maher TM
    Lancet; 2022 Sep; 400(10354):769-786. PubMed ID: 35964592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Interstitial lung diseases among patients hospitalized in the Department of Respiratory Medicine in Radom District Hospital during the years 2000-2009].
    Szafrański W
    Pneumonol Alergol Pol; 2012; 80(6):523-32. PubMed ID: 23109204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease: State of the Art and Future Directions.
    Castillo-Saldana D; Hague CJ; Coxson HO; Ryerson CJ
    J Thorac Imaging; 2020 Jul; 35(4):246-254. PubMed ID: 31397750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
    Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.